MaxCyte, Inc.
corporate_fare Company Profile
MaxCyte, Inc. (NASDAQ:MXCT) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 18 items for MXCT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for MXCT spans 10-Q, 8-K, SCHEDULE 13D, 10-K.
Recent high-impact activity:
- MaxCyte 10-Q: Q3 Revenue Up 49% to $10.2M, Net Loss Narrows to $4.8M Ahead of $151.8M Akron Deal
- MaxCyte Sinks 10% as $151.8M Akron Bio Buyout Dilutes Shareholders
- MaxCyte to Pay $151.8M for Akron Bio: $105M Cash, 20.6M Shares, $20M Deferred
- Q3 Revenue Jumps 49% to $10.2M, Full-Year Guidance Raised to at Least $34.5M
- MaxCyte to Buy Akron Bio, Expects Deal to Nearly Double Revenue Base
Financial Snapshot
Short Interest & Short Volume
1.34 days to coverFINRA reported short interest of 1,583,224 shares in MXCT as of the October 30, 2026 settlement, a 13.6% decrease from the prior period — about 1.3 days to cover at its recent average daily volume. On November 20, 2026, 11.1% of MXCT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.